Dova Pharmaceuticals Reports Second Quarter 2017 Operating and Financial Results
August 10, 2017 16:05 ET
|
Dova Pharmaceuticals, Inc.
NDA submission for avatrombopag expected in the third quarter of 2017 Conference call scheduled for 4:30 p.m. EDT today DURHAM, N.C., Aug. 10, 2017 (GLOBE NEWSWIRE) -- Dova Pharmaceuticals, Inc....
Dova Pharmaceuticals to Announce Second Quarter 2017 Financial Results on August 10, 2017
August 03, 2017 16:30 ET
|
Dova Pharmaceuticals, Inc.
DURHAM, N.C., Aug. 03, 2017 (GLOBE NEWSWIRE) -- Dova Pharmaceuticals, Inc. (NASDAQ:DOVA), a pharmaceutical company focused on acquiring, developing and commercializing drug candidates for rare...
Dova Pharmaceuticals, Inc. Announces Pricing of Initial Public Offering
June 28, 2017 22:36 ET
|
Dova Pharmaceuticals, Inc.
DURHAM, N.C., June 28, 2017 (GLOBE NEWSWIRE) -- Dova Pharmaceuticals, Inc. (NASDAQ:DOVA), a pharmaceutical company focused on acquiring, developing and commercializing drug candidates for rare...